sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
|
MAO inhibitor
|
dexfenfluramine
|
ADVISE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s2
|
DDI-DrugBank.d423.s2.p0
|
Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
|
quinolones
|
caffeine
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s0
|
DDI-DrugBank.d123.s0.p1
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
aspirin
|
warfarin
|
NONE
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p35
|
Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
|
cyclosporine
|
fibrate drugs
|
EFFECT
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s5
|
DDI-DrugBank.d283.s5.p3
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
triazolam
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p11
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
bromelains
|
methyldopa
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p376
|
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
|
dopamine
|
propranolol
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s4
|
DDI-DrugBank.d325.s4.p1
|
Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
|
Barbiturates
|
coumarin drugs
|
ADVISE
|
1109248.xml
|
DDI-MedLine.d106.s6
|
DDI-MedLine.d106.s6.p1
|
Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
|
anticoagulant
|
phenytoin
|
MECHANISM
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s89
|
DDI-DrugBank.d64.s89.p9
|
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
|
potassium-sparing diuretics
|
spironolactone
|
NONE
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s15
|
DDI-DrugBank.d334.s15.p5
|
Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
|
Auranofin
|
Solganal
|
ADVISE
|
Auranofin_ddi.xml
|
DDI-DrugBank.d374.s0
|
DDI-DrugBank.d374.s0.p1
|
It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
|
CASODEX
|
coumarin anticoagulants
|
ADVISE
|
Bicalutamide_ddi.xml
|
DDI-DrugBank.d266.s1
|
DDI-DrugBank.d266.s1.p0
|
Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
|
Analgesic
|
ibuprofen
|
NONE
|
Doxazosin_ddi.xml
|
DDI-DrugBank.d367.s9
|
DDI-DrugBank.d367.s9.p5
|
The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
|
dextromethorphan hydrobromide
|
psychotropics
|
EFFECT
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s2
|
DDI-DrugBank.d398.s2.p2
|
FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
|
FLUOTHANE
|
aminoglycosides
|
EFFECT
|
Halothane_ddi.xml
|
DDI-DrugBank.d74.s0
|
DDI-DrugBank.d74.s0.p1
|
Diflunisal decreased the hyperuricemic effect of furosemide.
|
Diflunisal
|
furosemide
|
EFFECT
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s8
|
DDI-DrugBank.d132.s8.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
clobazam
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p6
|
Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
|
Phenylbutazone
|
Phenylbutazone
|
NONE
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s19
|
DDI-DrugBank.d219.s19.p0
|
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
|
reserpine
|
beta-blocking
|
EFFECT
|
Betaxolol_ddi.xml
|
DDI-DrugBank.d489.s2
|
DDI-DrugBank.d489.s2.p0
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
telithromycin
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p10
|
- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.
|
bumetanide
|
aminoglycoside antibiotics
|
ADVISE
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s0
|
DDI-DrugBank.d331.s0.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
ibuprofen
|
naproxen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p967
|
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
|
iodine
|
antacids
|
NONE
|
Diatrizoate_ddi.xml
|
DDI-DrugBank.d293.s0
|
DDI-DrugBank.d293.s0.p8
|
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
|
Aprepitant
|
nefazodone
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s31
|
DDI-DrugBank.d382.s31.p2
|
The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion.
|
DCG-IV
|
PCP
|
EFFECT
|
11085328.xml
|
DDI-MedLine.d104.s4
|
DDI-MedLine.d104.s4.p0
|
Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
|
Nevirapine
|
rifampin
|
ADVISE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s53
|
DDI-DrugBank.d270.s53.p0
|
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
|
lomefloxacin
|
terfenadine
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s23
|
DDI-DrugBank.d516.s23.p8
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
lithium
|
norepinephrine
|
NONE
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p26
|
Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
|
Antacids
|
quinolones
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s6
|
DDI-DrugBank.d562.s6.p1
|
Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].
|
Trileptal
|
felodipine
|
MECHANISM
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s45
|
DDI-DrugBank.d307.s45.p2
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
rifampin
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p20
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
probenecid
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p5
|
Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
|
tricyclic antidepressants
|
cimetidine
|
EFFECT
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s22
|
DDI-DrugBank.d99.s22.p0
|
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
|
(S)-warfarin
|
warfarin
|
NONE
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s16
|
DDI-DrugBank.d216.s16.p9
|
Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
|
Ethoxzolamide
|
quinidine
|
EFFECT
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s0
|
DDI-DrugBank.d286.s0.p3
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
sirolimus
|
tacrolimus
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p76
|
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
|
omeprazole
|
cimetidine
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s5
|
DDI-DrugBank.d558.s5.p19
|
Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
|
diuretics
|
furosemide
|
NONE
|
Cefepime_ddi.xml
|
DDI-DrugBank.d378.s1
|
DDI-DrugBank.d378.s1.p2
|
A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
|
ritonavir
|
nevirapine
|
ADVISE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s39
|
DDI-DrugBank.d270.s39.p2
|
This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.
|
BEXTRA
|
ACE-inhibitors
|
ADVISE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s9
|
DDI-DrugBank.d328.s9.p0
|
Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.
|
theophylline
|
erythromycin
|
NONE
|
Cetirizine_ddi.xml
|
DDI-DrugBank.d393.s4
|
DDI-DrugBank.d393.s4.p3
|
Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
|
NSAIDs
|
beta-blockers
|
EFFECT
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s9
|
DDI-DrugBank.d85.s9.p4
|
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
|
Indinavir
|
Vardenafil
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s10
|
DDI-DrugBank.d198.s10.p5
|
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
|
pentazocine
|
Levo-Dromoran
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s6
|
DDI-DrugBank.d257.s6.p20
|
Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
|
cimetidine
|
isradipine
|
MECHANISM
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s7
|
DDI-DrugBank.d81.s7.p3
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
alcohol
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p0
|
Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.
|
Rifampin
|
losartan
|
MECHANISM
|
Losartan_ddi.xml
|
DDI-DrugBank.d30.s1
|
DDI-DrugBank.d30.s1.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
alprazolam
|
praziquantel
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p119
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
lithium
|
NSAIDs
|
NONE
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p27
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
mefenamic acid
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p25
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
quinidine
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p75
|
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
|
Cyclopropane
|
catecholamines
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s8
|
DDI-DrugBank.d325.s8.p1
|
These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
|
diltiazem
|
triazolam
|
EFFECT
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s35
|
DDI-DrugBank.d565.s35.p1
|
There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
|
anticoagulants
|
corticosteroids
|
EFFECT
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s8
|
DDI-DrugBank.d487.s8.p0
|
The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
|
dopamine HCl
|
alpha-adrenergic blocking agents
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s5
|
DDI-DrugBank.d325.s5.p0
|
Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
|
Corticotropin
|
diuretic
|
EFFECT
|
Corticotropin_ddi.xml
|
DDI-DrugBank.d25.s0
|
DDI-DrugBank.d25.s0.p0
|
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
|
Haloperidol
|
PCP
|
EFFECT
|
3968644.xml
|
DDI-MedLine.d30.s11
|
DDI-MedLine.d30.s11.p1
|
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
|
Sedatives
|
anesthetics
|
NONE
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s1
|
DDI-DrugBank.d197.s1.p11
|
Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
|
bosentan
|
S-warfarin
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s30
|
DDI-DrugBank.d289.s30.p3
|
Clinical implications of warfarin interactions with five sedatives.
|
warfarin
|
sedatives
|
INT
|
1109248.xml
|
DDI-MedLine.d106.s0
|
DDI-MedLine.d106.s0.p0
|
Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.
|
SULAR
|
phenytoin
|
ADVISE
|
Nisoldipine_ddi.xml
|
DDI-DrugBank.d106.s4
|
DDI-DrugBank.d106.s4.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
antacids
|
cholestyramine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p71
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
phenothiazines
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p8
|
Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
|
aminoglycoside antibiotics
|
cephalosporin antibiotics
|
EFFECT
|
Cefprozil_ddi.xml
|
DDI-DrugBank.d121.s0
|
DDI-DrugBank.d121.s0.p0
|
However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
|
PRECEDEX
|
hypnotic
|
ADVISE
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s4
|
DDI-DrugBank.d197.s4.p7
|
The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.
|
isosorbide mononitrate
|
vasodilators
|
EFFECT
|
Isosorbide Mononitrate_ddi.xml
|
DDI-DrugBank.d479.s0
|
DDI-DrugBank.d479.s0.p0
|
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
|
alcohol
|
sedatives
|
NONE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s1
|
DDI-DrugBank.d224.s1.p13
|
AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects.
|
calcium channel blocker
|
diltiazem
|
NONE
|
11180036.xml
|
DDI-MedLine.d86.s1
|
DDI-MedLine.d86.s1.p5
|
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.
|
digoxin
|
warfarin
|
NONE
|
Irbesartan_ddi.xml
|
DDI-DrugBank.d27.s0
|
DDI-DrugBank.d27.s0.p3
|
Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
|
diflunisal
|
indomethacin
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s20
|
DDI-DrugBank.d132.s20.p3
|
Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.
|
Levo-Dromoran
|
MAO inhibitors
|
ADVISE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s3
|
DDI-DrugBank.d257.s3.p2
|
In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
|
INDOCIN
|
thiazide diuretics
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s23
|
DDI-DrugBank.d82.s23.p2
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
tricyclic antidepressants
|
flecainide
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p5
|
Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
|
VIRACEPT
|
nelfinavir
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s16
|
DDI-DrugBank.d340.s16.p7
|
The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
|
phenothiazines
|
antidepressants
|
NONE
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s3
|
DDI-DrugBank.d335.s3.p13
|
Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.
|
digoxin
|
nicardipine HCl
|
ADVISE
|
Nicardipine_ddi.xml
|
DDI-DrugBank.d468.s5
|
DDI-DrugBank.d468.s5.p5
|
Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
|
TAMBOCOR
|
TAMBOCOR
|
NONE
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s19
|
DDI-DrugBank.d87.s19.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
contraceptives
|
topiramate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p922
|
These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.
|
antibiotics
|
anticholinesterase
|
ADVISE
|
Neostigmine_ddi.xml
|
DDI-DrugBank.d498.s1
|
DDI-DrugBank.d498.s1.p0
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
antineoplastic agents
|
anticoagulants
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p6
|
If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
|
cyclosporine
|
diltiazem
|
ADVISE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s27
|
DDI-DrugBank.d565.s27.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
dicumarol
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p13
|
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
|
Dexamethasone
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s3
|
DDI-MedLine.d12.s3.p1
|
Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
|
TRICOR
|
atorvastatin
|
MECHANISM
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s15
|
DDI-DrugBank.d283.s15.p3
|
Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.
|
lidocaine
|
Bretylium Tosylate
|
NONE
|
Bretylium_ddi.xml
|
DDI-DrugBank.d180.s3
|
DDI-DrugBank.d180.s3.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
magnesium
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p9
|
We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
|
4-methylpyrazole
|
1,3-difluoro-2-propanol
|
EFFECT
|
11170315.xml
|
DDI-MedLine.d125.s8
|
DDI-MedLine.d125.s8.p0
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
guanethidine
|
guanadrel
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p69
|
Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.
|
tricyclic antidepressants
|
cimetidine
|
MECHANISM
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s0
|
DDI-DrugBank.d202.s0.p0
|
Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
|
Ibuprofen
|
lithium
|
MECHANISM
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s12
|
DDI-DrugBank.d415.s12.p3
|
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
|
Levothyroxine Sodium
|
aluminum hydoxide
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s2
|
DDI-DrugBank.d411.s2.p1
|
For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
|
cholestyramine
|
vitamin K
|
MECHANISM
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s3
|
DDI-DrugBank.d64.s3.p1
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
diazepam
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p5
|
Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
furosemide
|
EFFECT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s11
|
DDI-DrugBank.d172.s11.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
oxcarbazepine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p30
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
pertechnetate
|
insulin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p193
|
Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
|
Argatroban
|
antiplatelet agents
|
EFFECT
|
Argatroban_ddi.xml
|
DDI-DrugBank.d148.s6
|
DDI-DrugBank.d148.s6.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
clofibrate
|
methylphenidate
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p638
|
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
|
Azithromycin
|
zidovudine
|
MECHANISM
|
11210404.xml
|
DDI-MedLine.d105.s7
|
DDI-MedLine.d105.s7.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
valproate
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p41
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.